Bad News

Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line interference of Metastatic Colorectal Cancer entropy from randomize clinical footraces have shown that cetuximab is active in metastatic colorectal cancer (mCRC). Promising results have been reported from level angle II studies that evaluated the safety and efficacy of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) in patients with mCRC. Therefore, investigators for the Oxaliplatin and Cetuximab in First-Line Treatment of mCRC (OPUS) field of force now report the results of an open-label, randomized, phase II study that compared the efficacy and safety of cetuximab cocksure FOLFOX-4 against FOLFOX-4 only as main(a) give-and-take for mCRC. In addition, a subgroup analysis was performed base on KRAS gene mutational status to determine its manifestation take to be for the cetuximab positivistic FOLFOX-4 regimen. The results showed that cetuximab plus FOL FOX-4 improved boilersuit response place (ORRs) when compared with FOLFOX-4 alone in patients with tumors conferring wild-type KRAS status. The OPUS trial involved 337 patients with antecedently untreated, nonresectable, epidermal growth factor receptor?positive mCRC. Patients from 79 centers were enrolled from July 2005 to March 2006.

The patients were randomly assigned to the cetuximab plus FOLFOX-4 group (n = 169) or to the FOLFOX-4 alone group (n = 168). Cetuximab was given on day 1 as a 2-hour infusion (400 mg/m2), followed by each week 1-hour infusions (250 mg/m2). The FOLFOX-4 regimen consisted of oxaliplatin (85 mg/m2 on day 1), leucovorin (200 mg/m2), and 5-fluorouracil (! 400 mg/m2 bolus followed by 600 mg/m2 infusion during 22 hours on days 1 and 2). The 2-week treatment cycles were repeated until disease development or unacceptable toxicity occurred. The primary endpoint was the ORR for cetuximab plus FOLFOX-4 vs FOLFOX-4 alone. KRAS mutational status was assessed in tumors of 233 patients by polymerase chain chemical reaction (cetuximab plus FOLFOX-4...If you need to get a full essay, severalize it on our website: BestEssayCheap.com

If you want to get a full essay, visit our page: cheap essay